REFERENCES
1. Buhtoiarov IN. Pediatric Lymphoma.Pediatr Rev 2017; 38: 410-423.
2. Thanarajasingam G, Bennani-Baiti N, Thompson CA. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma. Curr Treat Options Oncol 2016; 17: 24.
3. Kelly KM. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Blood2015; 126: 2452-2458.
4. Schwartz CL, Constine LS, Villaluna D et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009; 114: 2051-2059.
5. Kelly KM, Cole PD, Pei Q et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. Br J Haematol 2019; 187: 39-48.
6. Kahn JM, Kelly KM, Pei Q et al. Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children’s Oncology Group Study. J Clin Oncol2019; 37: 3009-3017.
7. Brepoels L, Stroobants S. PET scanning and prognosis in Hodgkin’s lymphoma. Curr Opin Oncol2008; 20: 509-516.
8. Bhojwani D, McCarville MB, Choi JK et al. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol 2015; 168: 845-853.
9. Fallanca F, Alongi P, Incerti E et al. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). Eur J Nucl Med Mol Imaging 2016; 43: 1837-1848.
10. Barnes JA, LaCasce AS, Zukotynski K et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma. Ann Oncol 2011; 22: 910-915.
11. Isik EG, Kuyumcu S. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of (18)FDG-PET/CT according to DeltaSUVmax, Deauville 5-point scale and IHP criteria. 2017; 31: 660-668.
12. Ferrari C, Niccoli Asabella A, Merenda N et al. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment. Medicine (Baltimore) 2017; 96: e5973.
13. Brepoels L, Stroobants S, De Wever W et al. Aggressive and indolent non-Hodgkin’s lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma 2007; 48: 1522-1530.
14. Brepoels L, Stroobants S, De Wever W et al. Hodgkin lymphoma: Response assessment by revised International Workshop Criteria. Leuk Lymphoma 2007; 48: 1539-1547.
15. Meignan M, Gallamini A, Meignan M et al. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009; 50: 1257-1260.
16. Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation.Leuk Lymphoma 2009; 50: 1761-1764.
17. Boellaard R, O’Doherty MJ, Weber WA et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.
18. Furth C, Amthauer H, Hautzel H et al. Evaluation of interim PET response criteria in paediatric Hodgkin’s lymphoma–results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 2011; 22: 1198-1203.
19. Gobbi PG, Ferreri AJ, Ponzoni M, Levis A. Hodgkin lymphoma. Crit Rev Oncol Hematol 2013; 85: 216-237.
20. Marr K, Ronsley R. Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma. 2020; 67: e28167.
21. Henderson TO, Parsons SK, Wroblewski KE et al. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis. Cancer 2018; 124: 136-144.
22. Kelly KM, Sposto R, Hutchinson R et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children’s Oncology Group. Blood 2011; 117: 2596-2603.
23. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
24. Lopci E, Mascarin M, Piccardo A et al. FDG PET in response evaluation of bulky masses in paediatric Hodgkin’s lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial. Eur J Nucl Med Mol Imaging 2019; 46: 97-106.
25. Cheson BD, Fisher RI, Barrington SF et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059-3068.
26. Schaefer NG, Taverna C, Strobel K et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy–is biopsy of FDG-avid lesions still needed? Radiology2007; 244: 257-262.
27. Jorgov L, Montravers F, Balogova S et al. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT. Eur J Nucl Med Mol Imaging 2016; 43: 1220-1230.
28. Zhang X, Fan W, Xia ZJ et al. Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy. Chin J Cancer 2015; 34: 70-78.
29. Ilivitzki A, Radan L, Ben-Arush M et al. Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT.Pediatr Radiol 2013; 43: 86-92.
30. Cerci JJ, Pracchia LF, Linardi CC et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010; 51: 1337-1343.
31. Engert A, Haverkamp H, Kobe C et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet2012; 379: 1791-1799.
32. Chang Y, Fu X, Sun Z et al. Utility of baseline, interim and end-of-treatment (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase. Sci Rep 2017; 7: 41057.
33. Hu YY, Zhang X, Long W et al. Cervical lymph node hyperplasia on [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography scan after treatment of children and adolescents with malignant lymphoma. Eur J Radiol2015; 84: 1378-1382.
34. Bakhshi S, Bhethanabhotla S, Kumar R et al. Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging. J Nucl Med 2017; 58: 577-583.
35. Kluge R, Chavdarova L, Hoffmann M et al. Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin’s Lymphoma. PLoS One 2016; 11: e0149072.
36. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials.Hematol Oncol Clin North Am 2007; 21: 841-854.
37. Barrington SF, Qian W, Somer EJ et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.Eur J Nucl Med Mol Imaging 2010; 37: 1824-1833.